시장보고서
상품코드
1954319

세포주 개발 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 프로세스별, 단계별, 구성 요소별, 기능별

Cell Line Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Component, Functionality

발행일: | 리서치사: Global Insight Services | 페이지 정보: 영문 327 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포주 개발 시장은 2024년 71억 달러에서 2034년까지 188억 달러로 확대되어 CAGR 약 10.1%를 나타낼 것으로 예측됩니다. 세포주 개발 시장은 바이오 의약품 제조, 연구 개발, 진단을 위한 안정적인 세포주 창출을 포함합니다. 이 시장은 생물학적 제형, 바이오시밀러, 맞춤형 의료에 대한 수요가 증가함에 따라 견인되고 있습니다. 주요 발전에는 유전자 편집 기술, 자동화, 높은 처리량 스크리닝의 진보가 포함됩니다. 만성 질환 증가와 효율성 및 규제 준수를 중시하는 혁신적인 치료 솔루션의 필요성으로 인해이 분야는 견조한 성장을 보이고 있습니다.

세포주 개발 시장은 바이오테크놀러지의 진보와 바이오의약품 수요 증가를 원동력으로 견조한 성장을 이루고 있습니다. 이 시장에서 배지 및 시약 부문은 최적화된 세포 배양 조건의 필요성으로 인해, 가장 높은 성장률을 나타내는 하위 부문으로서 두드러지고 있습니다. 설비 부문, 특히 생물반응기와 인큐베이터는 세포주 생산에서 정밀한 환경 제어의 필요성을 반영하고 이에 이어집니다. 재조합 세포주 하위 부문은 치료용 단백질 생산 및 백신 개발에 대한 응용에 의해 주요 촉진요인으로 상승하고 있습니다. 병행하여, 하이브리도마 하위 부문은 특히 단일클론항체 생산에서의 비용 효과 및 확장성으로 주목받고 있습니다. 또한, 맞춤형 의료의 진전은 설계된 세포주에 대한 수요를 촉진하고 혁신과 투자에 유망한 기회를 부각시키고 있습니다. 전략적 제휴와 혁신은 경쟁 구도 형성, 효율성 증진, 시장 확대에 매우 중요합니다.

시장 세분화
유형 재조합 세포주, 하이브리도마, 연속 세포주, 1차 세포주, 줄기 세포주, 불멸화 세포주
제품 배지 및 시약, 장비, 용기, 바이오리액터, 동결보존 바이알
서비스 세포주 특성화, 세포주 인증, 세포 은행, 세포주 시험
기술 CRISPR, 유전자 편집, 유동 세포 계측, 단일 세포 분석
응용 분야 바이오생산, 신약개발, 조직공학, 독성시험, 조사, 재생의료
최종 사용자 바이오의약품기업, 수탁연구기관, 학술기관 및 연구기관, 병원
프로세스 형질감염, 선택, 스크리닝, 증폭, 안정성 시험
단계 개발, 생산, 최적화, 스케일업
구성요소 세포 배양 배지, 무혈청 배지
기능성 유전자 발현, 단백질 생산, 항체 생산

세포주 개발 시장은 가격 전략과 혁신적인 제품의 도입이 시장 점유율에 크게 영향을 미치는 역동적인 시장 상황을 특징으로합니다. 주요 기업은 경쟁력 있는 가격 설정에 주력하고 최첨단 세포주 개발 솔루션을 투입함으로써 보다 큰 시장 점유율 획득을 목표로 하고 있습니다. 바이오 의약품 및 바이오시밀러에 대한 지속적인 관심이 수요를 뒷받침하고 있으며, 북미는 혁신과 제품 투입의 최전선에 위치하고 있습니다. 반면 아시아태평양은 투자 증가와 정부의 유리한 조치로 인해 주요 기업로 부상하고 있습니다. 세포주 개발 시장에서의 경쟁은 치열하고, 주요 기업은 기술적 우위성과 시장 지배력을 목표로 분투하고 있습니다. 각 회사는 자사 제품의 강화와 규제 준수를 유지하기 위해 서로 벤치마크를 실시했습니다. 북미와 유럽과 같은 지역의 규제 체제는 매우 중요하며 시장 역학을 형성하고 전략적 결정에 영향을 미칩니다. 엄격한 규제와 높은 개발 비용과 같은 과제는 있는 것, 유전자 치료나 맞춤형 의료의 진보에 견인되어 시장은 성장의 조짐을 보이고 있습니다.

주요 동향과 촉진요인:

세포주 개발 시장은 바이오 의약품 및 바이오시밀러에 대한 수요 증가를 배경으로 견조한 성장을 이루고 있습니다. CRISPR등의 유전자 편집 기술의 진보에 의해 개발 프로세스가 합리화되어, 정밀도와 효율성이 향상하고 있습니다. 이 기술적 진화는 치료제 생산에 중요한 요소인 원하는 특성을 가진 세포주를 만들 수 있습니다. 또 다른 중요한 동향은 제약 회사와 생명 공학 회사의 R&D 투자 증가입니다. 이 투자는 만성 질환에 대한 새로운 치료법의 개발을 목적으로 하며, 효율적인 세포주 개발의 필요성을 촉진하고 있습니다. 또한, 맞춤형 의료에 대한 관심 증가는 특정 환자 요구에 부응하는 세포주 공학의 혁신을 촉진하고 있습니다. 바이오의약품 생산에 대한 규제면의 지원도 중요한 추진력입니다. 각국 정부는 의약품 승인 프로세스의 신속화를 도모하는 정책을 실시하고 있어 시장 확대를 촉진하고 있습니다. 게다가 학술기관과 산업계의 연계가 세포주 기술의 진보를 촉진하고 있습니다. 이러한 파트너십은 연구 성과의 가속화와 상업적 성공으로의 전환에 매우 중요합니다. 이러한 상황에서 시장은 지속적인 성장이 예상되고 혁신과 발전 기회가 풍부하게 존재하고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

  • 거시경제 분석
  • 시장 동향
  • 시장 성장 촉진요인
  • 시장 기회
  • 시장 성장 억제요인
  • CAGR : 성장 분석
  • 영향 분석
  • 신흥 시장
  • 기술 로드맵
  • 전략적 프레임워크

제4장 부문 분석

  • 시장 규모 및 예측 : 유형별
    • 재조합 세포주
    • 하이브리도마
    • 연속 세포주
    • 1차 세포주
    • 줄기세포주
    • 불멸화 세포주
  • 시장 규모 및 예측 : 제품별
    • 배지 및 시약
    • 장비
    • 용기
    • 바이오리액터
    • 동결보존 바이알
  • 시장 규모 및 예측 : 서비스별
    • 세포주 특성화
    • 세포주 인증
    • 세포 은행
    • 세포주 시험
  • 시장 규모 및 예측 : 기술별
    • CRISPR
    • 유전자 편집
    • 유동 세포 계측
    • 단일 세포 분석
  • 시장 규모 및 예측 : 용도별
    • 바이오 생산
    • 신약개발
    • 조직공학
    • 독성시험
    • 조사
    • 재생 의료
  • 시장 규모 및 예측 : 최종 사용자별
    • 바이오의약품기업
    • 수탁연구기관
    • 학술기관 및 연구기관
    • 병원
  • 시장 규모 및 예측 : 프로세스별
    • 트랜스펙션
    • 선택
    • 스크리닝
    • 증폭
    • 안정성 시험
  • 시장 규모 및 예측 : 단계별
    • 개발
    • 생산
    • 최적화
    • 스케일업
  • 시장 규모 및 예측 : 컴포넌트별
    • 세포 배양 배지
    • 무혈청 배지
  • 시장 규모 및 예측 : 기능별
    • 유전자 발현
    • 단백질 생산
    • 항체 생산

제5장 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 라틴아메리카
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카
  • 아시아태평양
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주
    • 대만
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 남아프리카
    • 사하라 이남 아프리카
    • 기타 중동 및 아프리카

제6장 시장 전략

  • 수요 및 공급의 갭 분석
  • 무역 및 물류상의 제약
  • 가격, 비용, 마진의 동향
  • 시장 침투
  • 소비자 분석
  • 규제 개요

제7장 경쟁 정보

  • 시장 포지셔닝
  • 시장 점유율
  • 경쟁 벤치마킹
  • 주요 기업의 전략

제8장 기업 프로파일

  • Sartorius
  • Lonza
  • Wu Xi App Tec
  • Selexis
  • Bio Factura
  • Corning Incorporated
  • Thermo Fisher Scientific
  • Charles River Laboratories
  • Merck KGa A
  • Horizon Discovery
  • Abzena
  • Cell Culture Company
  • Promega Corporation
  • Gen Script Biotech
  • Eppendorf
  • Sartorius Stedim Biotech
  • GE Healthcare Life Sciences
  • Millipore Sigma
  • Cygnus Technologies
  • Lake Pharma

제9장 당사에 대해서

JHS 26.03.17

Cell Line Development Market is anticipated to expand from $7.1 billion in 2024 to $18.8 billion by 2034, growing at a CAGR of approximately 10.1%. The Cell Line Development Market encompasses the creation of stable cell lines for biopharmaceutical production, research, and diagnostics. This market is driven by the increasing demand for biologics, biosimilars, and personalized medicine. Key developments include advancements in gene editing technologies, automation, and high-throughput screening. The sector is witnessing robust growth due to the rising prevalence of chronic diseases and the need for innovative therapeutic solutions, emphasizing efficiency and regulatory compliance.

The Cell Line Development Market is experiencing robust growth, fueled by advancements in biotechnology and increasing demand for biopharmaceuticals. Within this market, the media and reagents segment stands out as the top-performing sub-segment, driven by the need for optimized cell culture conditions. The equipment segment, particularly bioreactors and incubators, follows closely, reflecting the necessity for precise environmental control in cell line production. The recombinant cell lines sub-segment is emerging as a key growth driver, propelled by its application in therapeutic protein production and vaccine development. In parallel, the hybridomas sub-segment is gaining traction, especially in monoclonal antibody production, owing to its cost-effectiveness and scalability. Furthermore, the rise in personalized medicine is fostering demand for engineered cell lines, highlighting a lucrative opportunity for innovation and investment. Strategic alliances and technological advancements are pivotal in shaping the competitive landscape, promoting efficiency, and expanding market reach.

Market Segmentation
TypeRecombinant Cell Lines, Hybridomas, Continuous Cell Lines, Primary Cell Lines, Stem Cell Lines, Immortalized Cell Lines
ProductMedia & Reagents, Equipment, Vessels, Bioreactors, Cryopreservation Vials
ServicesCell Line Characterization, Cell Line Authentication, Cell Banking, Cell Line Testing
TechnologyCRISPR, Gene Editing, Flow Cytometry, Single-cell Analysis
ApplicationBioproduction, Drug Discovery, Tissue Engineering, Toxicity Testing, Research, Regenerative Medicine
End UserBiopharmaceutical Companies, Contract Research Organizations, Academic & Research Institutes, Hospitals
ProcessTransfection, Selection, Screening, Amplification, Stability Testing
StageDevelopment, Production, Optimization, Scaling-Up
ComponentCell Culture Media, Serum-Free Media
FunctionalityGene Expression, Protein Production, Antibody Production

The Cell Line Development Market is characterized by a dynamic landscape where market share is significantly influenced by pricing strategies and the introduction of innovative products. Leading companies are focusing on competitive pricing and launching cutting-edge cell line development solutions to capture a larger share of the market. The ongoing focus on biologics and biosimilars is fueling demand, with North America at the forefront of innovation and product launches. Meanwhile, Asia-Pacific is emerging as a key player due to increased investments and favorable government initiatives. Competition in the Cell Line Development Market is intense, with major players striving for technological superiority and market dominance. Companies are benchmarking against each other to enhance their product offerings and maintain regulatory compliance. Regulatory frameworks in regions like North America and Europe are pivotal, shaping the market dynamics and influencing strategic decisions. The market is poised for growth, driven by advancements in gene therapy and personalized medicine, despite challenges such as stringent regulations and high development costs.

Geographical Overview:

The cell line development market is witnessing notable growth across various regions, each exhibiting unique characteristics. North America remains at the forefront, driven by robust research activities and substantial funding in biotechnology. The region's advanced healthcare infrastructure further propels market expansion, with the United States leading in innovation and technology adoption. Europe follows closely, with a strong emphasis on biopharmaceutical research and development. The region's regulatory framework supports market growth, fostering a conducive environment for cell line advancements. Countries like Germany and the United Kingdom are pivotal, contributing significantly to the market's expansion. In the Asia Pacific, the market is burgeoning, fueled by increasing investments in biotechnology and pharmaceutical sectors. China and India are emerging as key players, with a focus on enhancing healthcare capabilities and fostering innovation. Latin America and the Middle East & Africa are also witnessing growth, driven by rising healthcare demands and increasing investments in biotechnology.

The cell line development market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, the emphasis on biopharmaceutical innovation is prompting strategic investments in local cell line technologies to mitigate tariff-induced cost pressures. China is navigating export restrictions by bolstering its domestic cell line capabilities, while Taiwan's robust biotech sector remains pivotal yet vulnerable to geopolitical tensions. The global parent market is experiencing robust growth, driven by advancements in personalized medicine and biologics. By 2035, the market is anticipated to flourish, contingent on strategic regional collaborations and technological advancements. Middle East conflicts elevate energy prices, indirectly affecting operational costs and supply chain resilience, underscoring the necessity for diversified energy sources and logistics strategies.

Key Trends and Drivers:

The Cell Line Development Market is experiencing robust growth, fueled by the rising demand for biologics and biosimilars. Advances in gene editing technologies, such as CRISPR, are streamlining the development process, enhancing precision and efficiency. This technological evolution is enabling the creation of cell lines with desirable traits, a critical factor in therapeutic production. Another significant trend is the increasing investment in research and development by pharmaceutical and biotechnology companies. This investment is aimed at developing novel therapies for chronic diseases, thereby driving the need for efficient cell line development. Furthermore, the growing emphasis on personalized medicine is spurring innovations in cell line engineering, catering to specific patient needs. Regulatory support for biopharmaceutical production is also a key driver. Governments are implementing policies to expedite drug approval processes, thus encouraging market expansion. Additionally, collaborations between academic institutions and industry players are fostering advancements in cell line technologies. These partnerships are pivotal in accelerating research outcomes and translating them into commercial success. As such, the market is poised for sustained growth, with ample opportunities for innovation and development.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Component
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Recombinant Cell Lines
    • 4.1.2 Hybridomas
    • 4.1.3 Continuous Cell Lines
    • 4.1.4 Primary Cell Lines
    • 4.1.5 Stem Cell Lines
    • 4.1.6 Immortalized Cell Lines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Media & Reagents
    • 4.2.2 Equipment
    • 4.2.3 Vessels
    • 4.2.4 Bioreactors
    • 4.2.5 Cryopreservation Vials
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Line Characterization
    • 4.3.2 Cell Line Authentication
    • 4.3.3 Cell Banking
    • 4.3.4 Cell Line Testing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 Gene Editing
    • 4.4.3 Flow Cytometry
    • 4.4.4 Single-cell Analysis
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Bioproduction
    • 4.5.2 Drug Discovery
    • 4.5.3 Tissue Engineering
    • 4.5.4 Toxicity Testing
    • 4.5.5 Research
    • 4.5.6 Regenerative Medicine
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biopharmaceutical Companies
    • 4.6.2 Contract Research Organizations
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Hospitals
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Transfection
    • 4.7.2 Selection
    • 4.7.3 Screening
    • 4.7.4 Amplification
    • 4.7.5 Stability Testing
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Development
    • 4.8.2 Production
    • 4.8.3 Optimization
    • 4.8.4 Scaling-Up
  • 4.9 Market Size & Forecast by Component (2020-2035)
    • 4.9.1 Cell Culture Media
    • 4.9.2 Serum-Free Media
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Gene Expression
    • 4.10.2 Protein Production
    • 4.10.3 Antibody Production

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Component
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Component
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Component
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Component
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Component
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Component
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Component
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Component
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Component
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Component
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Component
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Component
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Component
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Component
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Component
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Component
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Component
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Component
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Component
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Component
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Component
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Component
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Component
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Component
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sartorius
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Wu Xi App Tec
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Selexis
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bio Factura
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Corning Incorporated
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Thermo Fisher Scientific
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Charles River Laboratories
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Merck KGa A
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Horizon Discovery
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Abzena
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cell Culture Company
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Promega Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Gen Script Biotech
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Eppendorf
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Sartorius Stedim Biotech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 GE Healthcare Life Sciences
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Millipore Sigma
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cygnus Technologies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lake Pharma
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제